Breaking News Instant updates and real-time market news.

DBVT

DBV Technologies

$9.80

0.17 (1.77%)

, AIMT

Aimmune

$25.93

2.43 (10.34%)

08:35
09/12/19
09/12
08:35
09/12/19
08:35

Aimmune Palforzia safety bodes well for DBV'S Viaskin Peanut, says SVB Leerink

SVB Leerink analyst Joseph Schwartz notes that FDA's Allergenic Products Advisory Committee released briefing documents pertaining to its upcoming AdCom panel discussion for Aimmune's (AIMT) Palforzia on Friday. Because efficacy has been robust for Palforzia, the analyst thinks investors will be acutely focused on safety, and believes the details surrounding Palforzia safety bode well for DBV Technologies' (DBVT) Viaskin Peanut as it could provide a convenient and safer alternative for peanut allergic patients. Despite slower onset of efficacy, Viaskin Peanut's favorable safety profile could promote longer-term use which previously has been shown to continue to improve on efficacy, he contends. Schwartz has an Outperform rating on DBV Technologies' shares.

DBVT

DBV Technologies

$9.80

0.17 (1.77%)

AIMT

Aimmune

$25.93

2.43 (10.34%)

  • 13

    Sep

DBVT DBV Technologies
$9.80

0.17 (1.77%)

06/17/19
GSCO
06/17/19
INITIATION
Target $14
GSCO
Buy
DBV Technologies initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.
06/17/19
06/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DBV Technologies (DBVT) initiated with a Buy at Goldman Sachs. 2. Amicus (FOLD) initiated with a Buy at H.C. Wainwright. 3. Viper Energy (VNOM) initiated with a Buy at SunTrust. 4. GNC Holdings (GNC) initiated with a Hold at Jefferies. 5. Eventbrite (EB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
WEDB
07/12/19
NO CHANGE
Target $79
WEDB
Outperform
Aimmune selloff on ICER report overdone, says Wedbush
Wedbush analyst Liana Moussatos views the selloff yesterday in shares of Aimmune Therapeutics as overdone. The Institute for Clinical and Economic Review on Wednesday released a final report on emerging desensitization treatments for peanut allergy and compared the clinical effectiveness and value of Aimmune's AR101, DBV Technologies' (DBVT) Viaskin and non-commercialized oral immunotherapy for treatment of peanut allergy, Moussatos tells investors in a research note. However, the ICER report excluded long-term desensitization and patient quality-of-life results for AR101 and hence failed to recognize the full value of AR101 immunotherapy for peanut allergy, says the analyst. She sees an "excellent entry point" into Aimmune shares following yesterday's selloff and reiterates an Outperform rating on the name wih a $79 price target.
08/05/19
HCWC
08/05/19
NO CHANGE
Target $25
HCWC
Buy
H.C. Wainwright reiterates Buy on DBV ahead of expected BLA resubmission
H.C. Wainwright analyst Andrew Fein says that as DBV Technologie (DBVT) moves forward towards an anticipated Biologics License Application resubmission for Viaskin Peanut in Q3, he continues to be supportive of the overall value, safety, and efficacy of the Viaskin Peanut program. Following organizational updates, a "straightforward BLA resubmission could refresh investors' confidence in management, while addressing the regulatory overhang," Fein tells investors in a research note. He reiterates a Buy rating on DBV shares with a $25 price target. His confidence in the Viaskin Peanut program has been based on "exceptional safety and sufficient efficacy to manage the risk of accidental exposure." The analyst believes these properties differentiate Viaskin Peanut from the peanut oral immunotherapy being developed by Aimmune (AIMT).
AIMT Aimmune
$25.93

2.43 (10.34%)

08/09/19
RBCM
08/09/19
NO CHANGE
Target $50
RBCM
Outperform
Aimmune price target lowered to $50 from $58 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Aimmune to $50 after its Q2 earnings miss, also reducing his launch expectations for AR101 based on the analysis of the "recent comparable drug launches into indications with a similar unmet need." The analyst still keeps his Outperform rating on the stock and sees AR101 as well positioned to "disrupt and build the peanut allergy desensitization market".
09/09/19
BARD
09/09/19
NO CHANGE
Target $64
BARD
Outperform
Aimmune added as a Fresh Pick, AdCom a binary event, says Baird
Baird analyst Brian Skorney Added Aimmune as a Fresh Pick ahead of Friday's AdCom event. The analyst said it will be mid-week briefing documents followed by Friday's meeting which he expects to be a binary event. He believes it should be a positive catalyst which could yield a 20-30% upside from its current price and he noted AR101 has shown robust efficacy in increasing the amount of peanut protein tolerated by patients during it PALISADE trial. Skorney reiterated his Outperform rating and $64 price target on Aimmune shares.
09/11/19
STFL
09/11/19
NO CHANGE
STFL
Hold
Aimmune briefing docs look 'pretty benign,' says Stifel
After the FDA posted briefing documents ahead of its Allergenic Products Advisory Committee Meeting on September 13 to review Aimmune Therapeutics' peanut allergen powder, Palforzia, Stifel analyst Derek Archila said the documents "seem pretty benign" and did not generate any new issues. He expects the focus of the Adcom to be on safety, which is not "new" news, and thinks the document release should provide some relief for shares given that the "worst case" scenario in terms of the panel may be off the table. He sees the risk/reward as less favorable once Palforzia is approved given the commercial/logistical challenges he sees ahead, added Archila, who keeps a Hold rating on Aimmune shares.
09/11/19
PIPR
09/11/19
NO CHANGE
Target $60
PIPR
Overweight
Piper says FDA briefing docs remove key underpinning of Aimmune bear thesis
Piper Jaffray analyst Christopher Raymond said the FDA's briefing documents for its upcoming panel review of AR101, now called Palforzia, are "benign, even surprisingly positive," and he feels even more confident about the chances for approval of Aimmune's peanut allergy treatment. A key point in the documents is that the FDA is directing the panel to look at reactions to accidental exposures as perhaps a better predictor of real world utility than a double blinded placebo controlled food challenge, said Raymond, who contends that this "singular statement...removes a key underpinning from the bear thesis which points to the imbalance of systemic allergic reactions." The analyst, who anticipates a 2020 approval and revenue of over $1.5B by 2025, keeps an Overweight rating and $60 price target on Aimmune shares.

TODAY'S FREE FLY STORIES

BA

Boeing

$344.09

-25.04 (-6.78%)

08:31
10/19/19
10/19
08:31
10/19/19
08:31
Periodicals
Boeing recovery getting 'a lot more complicated,' Barron's says »

Boeing shares fell on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GMVHF

GVC Holdings

$0.00

(0.00%)

08:27
10/19/19
10/19
08:27
10/19/19
08:27
Periodicals
GVC Holdings looking like 'a good bet,' Barron's says »

GVC Holdings' stock…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EYE

National Vision

$22.98

-0.94 (-3.93%)

08:19
10/19/19
10/19
08:19
10/19/19
08:19
Periodicals
Street sees National Vision as a buy, some shorts disagree, Barron's says »

National Vision has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CI

Cigna

$167.11

2.3 (1.40%)

, HUM

Humana

$289.59

4 (1.40%)

08:13
10/19/19
10/19
08:13
10/19/19
08:13
Periodicals
Healthcare stocks getting 'back on their feet,' Barron's says »

The sector is the second…

CI

Cigna

$167.11

2.3 (1.40%)

HUM

Humana

$289.59

4 (1.40%)

UNH

UnitedHealth

$245.59

1.84 (0.75%)

WCG

WellCare

$274.54

0.09 (0.03%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$123.03

1.47 (1.21%)

TEVA

Teva

$7.50

-0.26 (-3.35%)

AZN

AstraZeneca

$43.86

-0.25 (-0.57%)

BMY

Bristol-Myers

$53.02

0.6 (1.14%)

LLY

Eli Lilly

$108.68

0.24 (0.22%)

GSK

GlaxoSmithKline

$42.52

0.04 (0.09%)

JNJ

Johnson & Johnson

$127.73

-8.47 (-6.22%)

MRK

Merck

$84.68

0.88 (1.05%)

NVS

Novartis

$86.86

-0.395 (-0.45%)

PFE

Pfizer

$36.46

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

SNY

Sanofi

$46.13

-0.43 (-0.92%)

ANTM

Anthem

$249.55

0.3 (0.12%)

CVS

CVS Health

$66.17

-0.31 (-0.47%)

CNC

Centene

$46.92

-0.28 (-0.59%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 22

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

  • 14

    Nov

  • 18

    Nov

  • 07

    Dec

  • 24

    Jan

  • 24

    Jan

  • 14

    Mar

COP

ConocoPhillips

$53.99

-0.55 (-1.01%)

08:03
10/19/19
10/19
08:03
10/19/19
08:03
Periodicals
ConocoPhillips stock looking cheap following selloff, Barron's says »

At a time when Wall…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

  • 19

    Nov

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

, NFLX

Netflix

$275.40

-17.88 (-6.10%)

08:00
10/19/19
10/19
08:00
10/19/19
08:00
Periodicals
Comcast stacking up better than investors might expect, Barron's says »

If cord-cutting…

AMZN

Amazon.com

$1,757.77

-30.07 (-1.68%)

NFLX

Netflix

$275.40

-17.88 (-6.10%)

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$45.58

-0.36 (-0.78%)

T

AT&T

$38.46

0.64 (1.69%)

DIS

Disney

$130.91

-1.46 (-1.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 07

    Nov

  • 18

    Nov

  • 19

    Nov

  • 21

    Nov

AKS

AK Steel

$2.45

0.055 (2.30%)

, MT

ArcelorMittal

$14.58

0.03 (0.21%)

07:41
10/19/19
10/19
07:41
10/19/19
07:41
On The Fly
Week in Review: How Trump's policies moved stocks »

Catch up on the top…

AKS

AK Steel

$2.45

0.055 (2.30%)

MT

ArcelorMittal

$14.58

0.03 (0.21%)

NUE

Nucor

$51.69

-0.11 (-0.21%)

STLD

Steel Dynamics

$28.71

-0.04 (-0.14%)

TMST

TimkenSteel

$5.42

-0.015 (-0.28%)

X

U.S. Steel

$10.72

0.1 (0.94%)

GM

General Motors

$36.19

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 29

    Oct

  • 31

    Oct

  • 01

    Nov

AAVMY

ABN Amro

$0.00

(0.00%)

, BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

04:55
10/19/19
10/19
04:55
10/19/19
04:55
Conference/Events
Institute of International Finance to hold annual meeting »

2019 IIF Annual Meeting…

AAVMY

ABN Amro

$0.00

(0.00%)

BBVA

Banco Bilbao

$5.38

0.07 (1.32%)

BCS

Barclays

$8.48

0.11 (1.31%)

BLK

BlackRock

$445.26

-5.56 (-1.23%)

BNPQY

BNP Paribas

$0.00

(0.00%)

C

Citi

$69.76

0.16 (0.23%)

CAIXY

CaixaBank

$0.00

(0.00%)

CIB

Bancolombia

$49.65

0.12 (0.24%)

CS

Credit Suisse

$12.34

0.045 (0.37%)

EV

Eaton Vance

$44.07

-0.49 (-1.10%)

GS

Goldman Sachs

$206.61

0.13 (0.06%)

HSBC

HSBC

$38.72

-0.165 (-0.42%)

JPM

JPMorgan

$120.60

0.21 (0.17%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

MCO

Moody's

$217.41

-1.33 (-0.61%)

MS

Morgan Stanley

$43.70

0.25 (0.58%)

NYT

New York Times

$29.76

0.21 (0.71%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

RBS

RBS

$6.14

0.205 (3.46%)

RY

Royal Bank of Canada

$81.49

0.38 (0.47%)

SMFG

Sumitomo Mitsui

$6.87

-0.04 (-0.58%)

SPGI

S&P Global

$250.62

-2.15 (-0.85%)

STT

State Street

$63.40

3.69 (6.18%)

UBS

UBS

$11.35

0.09 (0.80%)

V

Visa

$175.83

-2.11 (-1.19%)

ZURVY

Zurich Insurance

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 22

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 25

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 04

    Nov

  • 06

    Nov

  • 10

    Nov

  • 12

    Nov

  • 21

    Nov

  • 04

    Dec

  • 10

    Dec

  • 07

    Jan

  • 14

    Jan

  • 14

    Jan

STT

State Street

$63.40

3.69 (6.18%)

20:09
10/18/19
10/18
20:09
10/18/19
20:09
Upgrade
State Street rating change at Keefe Bruyette »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

SUN

Sunoco

$32.43

0.32 (1.00%)

19:53
10/18/19
10/18
19:53
10/18/19
19:53
Upgrade
Sunoco rating change at BMO Capital »

Sunoco upgraded to Market…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:24
10/18/19
10/18
18:24
10/18/19
18:24
Hot Stocks
Tandy Leather CFO Castillo to step down »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TLF

Tandy Leather

$4.61

(0.00%)

18:23
10/18/19
10/18
18:23
10/18/19
18:23
Hot Stocks
Tandy Leather says most recent annual report statements not reliable »

Tandy Leather Factory…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$236.29

0.99 (0.42%)

18:03
10/18/19
10/18
18:03
10/18/19
18:03
Hot Stocks
U.S. lawmakers request Apple restore HKMapp app in Hong Kong »

U.S. Senators Ron Wyden,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

JPM

JPMorgan

$120.60

0.21 (0.17%)

, FB

Facebook

$185.96

-4.435 (-2.33%)

17:59
10/18/19
10/18
17:59
10/18/19
17:59
Periodicals
JPMorgan CEO says Libra 'a neat idea that will never happen,' Reuters says »

JPMorgan (JPM) CEO Jamie…

JPM

JPMorgan

$120.60

0.21 (0.17%)

FB

Facebook

$185.96

-4.435 (-2.33%)

PYPL

PayPal

$101.25

-2.38 (-2.30%)

MA

MasterCard

$270.90

-5.74 (-2.07%)

V

Visa

$175.83

-2.11 (-1.19%)

EBAY

eBay

$38.82

-0.31 (-0.79%)

BKNG

Booking Holdings

$2,012.20

-16.43 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 27

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 04

    Nov

  • 21

    Nov

  • 14

    Jan

GLD

SPDR Gold Shares

$140.47

-0.13 (-0.09%)

17:52
10/18/19
10/18
17:52
10/18/19
17:52
Hot Stocks
SPDR Gold Shares holdings rise to 924.64MT from 918.19MT »

This is the first…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TECK

Teck Resources

$16.48

0.11 (0.67%)

17:43
10/18/19
10/18
17:43
10/18/19
17:43
Hot Stocks
Teck Resources gets approval for stock buyback for up to 40M class B shares »

Teck Resources has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

OSK

Oshkosh

$77.22

0.46 (0.60%)

17:41
10/18/19
10/18
17:41
10/18/19
17:41
Hot Stocks
Oshkosh awarded $159.14M Army contract for medium tactical vehicle production »

Oshkosh was awarded a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Oct

  • 19

    Nov

  • 20

    Nov

OVLY

Oak Valley Bancorp

$16.40

-0.16 (-0.97%)

17:35
10/18/19
10/18
17:35
10/18/19
17:35
Earnings
Oak Valley Bancorp reports Q3 EPS 40c vs. 37c last year »

Reports Q3 NII $10.4M vs.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FTNW

FTE Networks

$0.79

-0.0185 (-2.29%)

17:21
10/18/19
10/18
17:21
10/18/19
17:21
Hot Stocks
FTE Networks receives noncompliance notice from NYSE American »

FTE Networks announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TNXP

Tonix Pharmaceuticals

$0.45

0.0048 (1.07%)

17:12
10/18/19
10/18
17:12
10/18/19
17:12
Syndicate
Breaking Syndicate news story on Tonix Pharmaceuticals »

Tonix Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLMD

Relmada Therapeutics

$20.18

1.07 (5.60%)

17:10
10/18/19
10/18
17:10
10/18/19
17:10
Syndicate
Breaking Syndicate news story on Relmada Therapeutics »

Relmada Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:55
10/18/19
10/18
16:55
10/18/19
16:55
General news
Breaking General news story  »

Dallas Federal Reserve…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

, NWS

News Corp

$13.79

-0.11 (-0.79%)

16:51
10/18/19
10/18
16:51
10/18/19
16:51
Periodicals
Facebook reaches pact with News Corp., others for news section, WSJ says »

News Corp. (NWSA) has…

NWSA

News Corp.

$13.48

-0.19 (-1.39%)

NWS

News Corp

$13.79

-0.11 (-0.79%)

FB

Facebook

$185.96

-4.435 (-2.33%)

NYT

New York Times

$29.76

0.21 (0.71%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 23

    Oct

  • 27

    Oct

  • 30

    Oct

  • 06

    Nov

WAIR

Wesco Aircraft

$11.01

0.01 (0.09%)

16:46
10/18/19
10/18
16:46
10/18/19
16:46
Conference/Events
Wesco Aircraft to host special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

FOMX

Foamix

$3.15

-0.09 (-2.78%)

16:41
10/18/19
10/18
16:41
10/18/19
16:41
Hot Stocks
Breaking Hot Stocks news story on Foamix »

Foamix up 7.5% at $3.35…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

  • 20

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.